Saro Kasparian
Overview
Explore the profile of Saro Kasparian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shao J, Xu Y, Olsen R, Kasparian S, Sun K, Mathur S, et al.
Cells
. 2024 Apr;
13(8.
PMID: 38667328
Immune checkpoint inhibitors (ICIs) drastically improve therapeutic outcomes for lung cancer, but accurately predicting individual patient responses to ICIs remains a challenge. We performed the genome-wide profiling of 5-hydroxymethylcytosine (5hmC)...
2.
Shao J, Olsen R, Kasparian S, He C, Bernicker E, Li Z
Cells
. 2024 Feb;
13(4.
PMID: 38391911
Accurate prognostic markers are essential for guiding effective lung cancer treatment strategies. The level of 5-hydroxymethylcytosine (5hmC) in tissue is independently associated with overall survival (OS) in lung cancer patients....
3.
Rainone M, Kasparian S, Nguyen T, Talwar N, Yuan Y, Mei M, et al.
Oncologist
. 2023 Jun;
28(9):e843-e846.
PMID: 37335880
Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that...
4.
Rainone M, Behrendt C, Kasparian S, Nguyen T, Sedrak M, Lavasani S, et al.
Breast Cancer
. 2023 Jun;
30(5):796-801.
PMID: 37326930
Background: Thrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1). A reported association of Asian ancestry with this event merits investigation to rule...
5.
Dorff T, Kasparian S, Garg N, Liu S, Pal S, Wong J, et al.
J Clin Med
. 2023 Mar;
12(5).
PMID: 36902798
Background: Metastasis-directed therapy is widely utilized for oligometastatic prostate cancer patients, but standard imaging does not always identify metastases definitively and, even with PSMA PET, there may be equivocal findings....
6.
Kasparian S, Wei O, Tsai N, Palmer J, Pal S, Lyou Y, et al.
Oncologist
. 2023 Mar;
28(8):699-705.
PMID: 36888587
Background: Relugolix is the newest form of androgen deprivation therapy (ADT) approved for prostate cancer. However, as an oral drug, several real-world concerns exist, particularly medication compliance, safety with other...
7.
Kasparian S, Gentille C, Burns E, Bernicker E
JTO Clin Res Rep
. 2021 Sep;
1(2):100017.
PMID: 34589924
Introduction: Immune-checkpoint inhibitors (ICIs) are transforming the modern era of cancer therapy. As new treatment options are becoming available, new patterns of disease behavior are manifesting. One such phenomenon, known...
8.
Kasparian S, Burns E, Shehabeldin A, Awar M, Pingali S
J Med Case Rep
. 2020 Aug;
14(1):127.
PMID: 32782017
Background: Acute small bowel obstruction is a common surgical emergency usually caused by abdominal adhesions, followed by intraluminal tumors from metastatic disease. Although lymphomas have been known to cause bowel...
9.
Burns E, Kasparian S, Khan U, Abdelrahim M
World J Clin Oncol
. 2020 Mar;
11(2):83-90.
PMID: 32133277
Background: Pancreatic adenocarcinoma is an aggressive malignancy with a high propensity to metastasize. Esophageal metastasis manifesting as dysphagia is rarely reported in the literature and has not to our knowledge...
10.
Burns E, Gentille C, Kasparian S, Pingali S
Case Rep Hematol
. 2019 Nov;
2019:7834728.
PMID: 31687231
Histiocytic sarcoma (HS) is an uncommon malignant neoplasm arising from mature histiocytes and most commonly characterized by the immunophenotypic expression of CD68, CD163, or lysozyme. Although rare, HS arising as...